2010 - Novel insights in pulmonary fibrogenesis: from bench to bedside Research Seminar

The aim of this seminar was to offer general discussion on emerging clinical and scientific concepts in pulmonary fibrosis including:

advances in autoimmune and idiopathic fibrosis with regard to both pathogenesis and treatment
diagnostic and prognostic evaluation, monitoring, and current and novel treatment approaches in idiopathic and autoimmune disease
recent important clinical statements and studies
laboratory science with s focus on the pathogenesis of fibrosis

2010 - Novel insights in pulmonary fibrogenesis: from bench to bedside Research Seminar

2023 - In Vitro Diagnostic (IVD) tests to combat antimicrobial resistance in community-acquired low-respiratory tract infections (CA-LRTI)

2024 - Sleep apnea and its consequences: from animal models to precision medicine

2019 - New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine

Welcome by ERS President

N. Siafakas (Heraklion, Greece)

Slides

Accompanying documents

Pulmonary fibrosis: ongoing trials and future treatment

V. Cottin (Lyon, France)

Accompanying documents

CON - Animal models: are they still useful?

T. Maher (St Albans, United Kingdom)

Slides

Accompanying documents

Genetics of pulmonary fibrosis

M. Petrek (Olomouc, Czech Republic)

Accompanying documents

A plethora of pathways, a medley of mediators: how do we tease out pathogenesis

G. Laurent (London, United Kingdom)

Accompanying documents

The current classification of the idiopathic interstitial pneumonias: has it advanced pathogenetic understanding

O. Eickelberg (Munich, Germany)

Slides

Accompanying documents

Epithelial mesenchymal transition

M. Keane (Dublin, Ireland)

Slides

Accompanying documents

Oxidant/Antioxidant imbalance: a potential contributor to pulmonary fibrosis

J. Behr (Munich, Germany)

Slides

Accompanying documents

Phospholipid homeostasis and IPF pathogenesis

V. Aidinis (Vari, Greece)

Accompanying documents

Is TGFb a central mediator in the development of pulmonary fibrosis?

G. Jenkins (Nottingham, United Kingdom), A. Tatler (Nottingham, United Kingdom)

Slides

Accompanying documents

IPF and lung cancer: what are the links?

V. Poletti (Forli, Italy)

Accompanying documents

HRCT in the diagnosis of diffuse lung disease - overlap issues

D. Hansell (London, United Kingdom)

Slides

Accompanying documents

Non invasive biomarkers in the diagnostic and prognostic evaluation of Pulmonary Fibrosis

S. Loukides (Athens, Greece)

Slides

Accompanying documents

Smoking and pulmonary fibrosis

K. Antoniou (Heraklion, Greece)

Slides

Accompanying documents

Pulmonary hypertension in Pulmonary Fibrosis: detection & treatment

Z. Daniil (Larissa, Greece)

Slides

Accompanying documents

Unresolved controversies: the unwritten pages

A. Wells (London, United Kingdom)

Slides

Accompanying documents

The management of IPF

D. Bouros (Alexandroupolis, Greece)

Slides

Accompanying documents

The diagnosis of IPF: recommendations & rationale

L. Richeldi (Modena, Italy); P. Spagnolo (Modena, Italy)

Slides

Accompanying documents

Bronchoalvolar Lavage (BAL) in diffuse lung disease: Pros & Cons

C. Robalo Cordeiro (Coimbra, Portugal)

Slides

Accompanying documents

Prognostic evaluation in connective tissue disease: a pragmatic algorithm

V. Cottin (Lyon, France)

Accompanying documents

Prognostic evaluation of idiopathic interstitial pneumonia: emerging data

A. Wells (London, United Kingdom)

Slides

Accompanying documents

The clinican's dilemma - when is biopsy required?

V. Poletti (Forli, Italy)

Slides

Accompanying documents

Histological diagnosis in diffuse lung disease - how pathologists think

A. Nicholson (London, United Kingdom)

Slides

Accompanying documents

2010 - Novel insights in pulmonary fibrogenesis: from bench to bedside Research Seminar

2010 - Novel insights in pulmonary fibrogenesis: from bench to bedside Research Seminar

#{title}